Steve Davis: Yeah. Thanks much for the question. Brendan, do you want to take that?
Brendan Teehan: Sure. Thanks. Thanks for the question. Many times in a rare disease, you would expect it to be a little challenging on where you find your patients. We do not see that in the Rett community. This is a well-organized group with advocacy groups that have membership lists well into the thousands. We have already identified the 4,500 or so already diagnosed and cared for patients in the United States. So, from that perspective, we don’t see finding where to locate our patients as Rett limiting. When you think in terms of both the prescribing community and where we are going to find those Rett patients, they do, as you pointed out, break into three principal groups. The first would be those centers of excellence, of which there are 22 currently designated and there are roughly 25% of the Rett population treated in those centers.
The vast majority of patients are then treated at high volume institutions, principally academic centers and children’s hospitals with strong neuroscience capabilities. And then there’s a smaller percentage of patients that are treated at individual neurology practices. So that’s principally how the audience breaks out.
Tessa Romero: And then do you expect kind of the cadence of patients starting treatment to be different dependent on type of practice, just as a quick follow-up.
Brendan Teehan: A fair question. A couple of things. I think we would expect given the results of the LAVENDER program that we would see a motivated group of families with patients that are on the younger end of the spectrum. So I wouldn’t be surprised if we skew towards younger patients and younger families in the early days for treatment. Also with the volumes that we are seeing at centers of excellence and at these high volume institutions, that’s where we principally expect the majority of patients to be given the opportunity to be treated with trofinetide in the early days. That is, I think, important to be — it’s important to understand that while there is a high interest in treatment, we will still be working through access with each of the payer organizations and the logistics of family simply getting to these facilities to have an opportunity to be treated.
Operator: Thank you. One moment for our next question. Our next question comes from the line of Marc Goodman from SVB Leerink.
Marc Goodman: Just as a follow-up on these 4,500 diagnosed and cared for patients. That number seems to be the same number that you all have been using for in the past year or so. I was just curious as you have kind of dug into this market, is that just a number that you are just using conservatively or are you finding more patients and it just seems like as you would look over the past years I would have
Brendan Teehan: We have access to databases, so we are able to track, diagnose and treated patients with Rett. As mentioned in the prepared remarks, there’s a prevalent population of 6,000 to 9,000 and it is not uncommon after the introduction of a first-to-market therapy that there could be an increase in diagnosis rates, particularly in older patients who may have been clinically diagnosed earlier on in life, but for which there hasn’t been perhaps a confirmatory genetic test. Other than that, using the claims database is available to us while there is an incident population that will be introduced over time. It’s still roughly in the 4,500 or so range for those diagnosed and treated in the United States. The separate question you had refers to NUPLAZID and LTC, and I think, we are encouraged by the early signs we have seen on two fronts.
